Short Interest in ENDRA Life Sciences Inc. (NASDAQ:NDRA) Rises By 27.0%

ENDRA Life Sciences Inc. (NASDAQ:NDRA) saw a significant increase in short interest in February. As of February 13th, there was short interest totaling 58,719 shares, an increase of 27.0% from the January 29th total of 46,244 shares. Currently, 8.7% of the shares of the company are sold short. Based on an average daily volume of 23,319 shares, the days-to-cover ratio is presently 2.5 days. Based on an average daily volume of 23,319 shares, the days-to-cover ratio is presently 2.5 days. Currently, 8.7% of the shares of the company are sold short.

Hedge Funds Weigh In On ENDRA Life Sciences

An institutional investor recently bought a new position in ENDRA Life Sciences stock. Altium Capital Management LLC acquired a new stake in shares of ENDRA Life Sciences Inc. (NASDAQ:NDRA) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences comprises approximately 0.9% of Altium Capital Management LLC’s investment portfolio, making the stock its 17th biggest position. Altium Capital Management LLC owned approximately 6.92% of ENDRA Life Sciences as of its most recent SEC filing. 1.19% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of ENDRA Life Sciences in a report on Wednesday, January 21st. Ascendiant Capital Markets decreased their price target on ENDRA Life Sciences from $38.00 to $30.00 and set a “buy” rating on the stock in a research report on Monday, December 8th. Finally, Wall Street Zen upgraded shares of ENDRA Life Sciences to a “sell” rating in a research report on Saturday, November 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $30.00.

ENDRA Life Sciences Stock Down 5.5%

NASDAQ:NDRA opened at $3.64 on Thursday. The stock has a market cap of $2.73 million, a P/E ratio of -0.14 and a beta of -0.08. The business’s 50-day moving average price is $4.19 and its two-hundred day moving average price is $4.95. ENDRA Life Sciences has a twelve month low of $2.90 and a twelve month high of $11.96.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.